Bristol-Myers Squibb BMY Short-term debt and current portion of long-term debt
Short-term debt and current portion of long-term debt at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:DebtCurrent.
The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's short-term debt and current portion of long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's short-term debt and current portion of long-term debt?
- Bristol-Myers Squibb (BMY) reported short-term debt and current portion of long-term debt of $2.31B in Q1 2026.
- How has Bristol-Myers Squibb's short-term debt and current portion of long-term debt changed year-over-year?
- Bristol-Myers Squibb's short-term debt and current portion of long-term debt decreased by 35.1% year-over-year, from $3.55B to $2.31B.
- What is the long-term trend for Bristol-Myers Squibb's short-term debt and current portion of long-term debt?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's short-term debt and current portion of long-term debt has grown at a -0.7% compound annual growth rate (CAGR), from $2.34B to $2.26B.
- What does short-term debt and current portion of long-term debt mean?
- The total amount of debt that must be paid back within one year.
- How do you interpret short-term debt and current portion of long-term debt?
- A decrease is generally positive as it reduces immediate liquidity risk, while a significant increase may signal refinancing needs or tighter cash flow.
- How does short-term debt and current portion of long-term debt compare across companies?
- Monitored closely by credit analysts to assess a company's ability to meet short-term obligations without refinancing.